Bortezomib

The addition of bortezomib to oral melphalan and dexamethasone improved hematologic response rates and OS among patients with systemic light-chain amyloidosis, according to phase 3 study results published in Journal of Clinical Oncology.

Chemotherapy-induced peripheral neuropathy is a potentially debilitating consequence of many cytotoxic drugs for the treatment of cancer.

Induction therapy with lenalidomide, bortezomib and dexamethasone demonstrated high response rates after transplantation among 90% of a cohort of patients with myeloma, according to study results published in Journal of Clinical Oncology.

Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly bortezomib and dexamethasone for pretreated multiple myeloma, according to results presented during the ASCO20 Virtual Scientific Program.

March is Myeloma Awareness Month.

The addition of selinexor to bortezomib and dexamethasone significantly extended PFS among patients with multiple myeloma who received one to three prior lines of therapy, according to randomized phase 3 study results released by the agent’s manufacturer.

Response-adapted intensification treatment with a bortezomib-based regimen improved PFS among patients with newly diagnosed multiple myeloma who achieved minimal or partial response to immunomodulatory induction therapy, according to results of a randomized phase 3 study published in The Lancet Haematology.

ORLANDO – The addition of venetoclax to standard of care regimens in multiple myeloma did not increase the physical burden on patients, according to a poster presenter at the ASH Annual Meeting and Exposition.

ORLANDO — The addition of daratumumab to lenalidomide, bortezomib and dexamethasone significantly improved rates of stringent clinical response and minimal disease negativity among patients with transplant-eligible newly diagnosed multiple myeloma, according to results of the randomized phase 2 GRIFFIN study presented at ASH Annual Meeting and Exposition.

The combination of bortezomib and vorinostat appeared safe and showed moderate activity among patients with diffuse large B-cell lymphoma and mantle cell lymphoma, according to a nonrandomized multicenter phase 2 trial.